Skip to main content

Table 5 The AUROC values of prediction methods for significant fibrosis, advanced fibrosis and cirrhosis in the validation cohort

From: Cytokeratin 18 can help predict liver fibrosis in HCV infected patients with type 2 diabetes mellitus

 

Significant fibrosis (F0-1 vs F2-4)

Advanced fibrosis (F0-2 vs F3-4)

Cirrhosis (F0-3 vs F4)

TE

0.96 (0.92, 0.99)

0.95 (0.92, 0.99)

0.93 (0.87, 0.98)

APRI

0.61 (0.50, 0.73)

0.58 (0.47, 0.68)

0.65 (0.55, 0.75)

FIB-4

0.65 (0.53, 0.76)

0.61 (0.51, 0.71)

0.67 (0.57, 0.77)

TE + CK18

0.97 (0.94, 0.99)

0.95 (0.91, 0.99)

0.93 (0.88, 0.98)

APRI + CK18

0.83 (0.75, 0.92)

0.69 (0.59, 0.79)

0.66 (0.56, 0.77)

FIB-4 + CK18

0.84 (0.77, 0.92)

0.74 (0.65, 0.83)

0.77 (0.69, 0.86)

Comparison of AUROC

   

 TE and TE + CK18

.32

.60

.40

 APRI and APRI + CK18

< .001

.19

.89

 FIB-4 and FIB-4 + CK18

< .001

.02

.03

  1. Numbers in parentheses are the 95% confidence interval
  2. AUROC, area under the receiver operating characteristic; APRI, aspartate transaminase-to-platelet ratio; CK18, cytokeratin 18; FIB-4, fibrosis-4 index; TE, transient elastography